AIP · Arteris, Inc. · Stock research

Current Thesis

Arteris licenses the network-on-chip (NoC) interconnect IP that stitches the compute blocks inside modern SoCs together, and collects a per-unit variable royalty each time a licensed chip ships. Royalties trail design wins by roughly 18-24 months, so the 2023-24 custom-silicon and ADAS win wave is only now converting to revenue. Q1 2026 (reported 2026-05-12) confirmed the inflection: revenue $22.9M (+39% YoY, ~8% above the ~$21M consensus), variable royalties +67% YoY, ACV+royalties $92.8M (+39%), RPO $118.3M (+33%), and a raised FY26 guide of $91-95M with positive free cash flow. The fundamental story is accelerating.

The tape is the problem. Price ran that inflection vertically to a $48.59 closing ATH (2026-06-30), then reversed ~29% in a week and closed back below the ~$39 shelf it had broken out from. That failed breakout leaves the momentum leg broken while the Q2 print (~2026-08-04, est.) sits roughly a week and a half out. A fresh long here buys a broken structure into a binary royalty print with little reward for the timing risk. The setup is a pass until the name either repairs a base and reclaims ~$39, or delivers a clean post-print continuation.

Bullish and bearish views on Arteris, Inc.

The model's bull view on Arteris, Inc. (AIP), in brief: Q1 2026 (2026-05-12): revenue $22.9M, +39% YoY, ~8% above the ~$21M consensus, EPS -$0.03 vs -$0.09 expected — a clean beat and an acceleration off the FY25 +22% pace. The bear view: The breakout failed. After the $48.59 closing ATH (2026-06-30), price collapsed ~29% in a week and closed back under the ~$39 shelf it launched from. Losing the base a breakout was built on is a structural break, not a routine pullback. The top was a one-week blowoff. A +11.9%… Both cases follow in full.

Bull Case

• Q1 2026 (2026-05-12): revenue $22.9M, +39% YoY, ~8% above the ~$21M consensus, EPS -$0.03 vs -$0.09 expected — a clean beat and an acceleration off the FY25 +22% pace.
• Variable royalties +67% YoY in Q1 — the lead KPI accelerated hard, the strongest evidence that prior design wins are converting to shipped chip volume. This single line carries the thesis.
• ACV + royalties $92.8M (+39%), RPO $118.3M (+33%) — contracted backlog grew in step with revenue, giving the acceleration forward visibility rather than a one-quarter pop.
• FY26 guide raised to $91-95M with positive FCF; Q2 guide $23-24M — a beat-and-raise quarter guiding to continued sequential growth.
• Design-win cadence keeps landing: the 2026-07-14 Arm partnership expansion (security assurance for processor-core development) deepens ecosystem lock-in, stacking on late-June SiEngine FlexNoC licensing for a next-gen automotive SoC, the June Li Auto L9 win, and Q1-call wins spanning a global hyperscaler, a top HBM supplier, a MIPS physical-AI collaboration, and NoC IP on NASA Artemis.
• Sell-side re-rated up through Q2: TD Cowen $40 (from $22), Rosenblatt $38 Buy (from $20), Northland $38, Jefferies $35 (from $16); consensus Buy, ~$37.75 average target.

Bear Case

• The breakout failed. After the $48.59 closing ATH (2026-06-30), price collapsed ~29% in a week and closed back under the ~$39 shelf it launched from. Losing the base a breakout was built on is a structural break, not a routine pullback.
• The top was a one-week blowoff. A +11.9% spike to fresh highs (2026-06-12) followed two weeks later by -10.7% and -16.4% sessions is parabolic exhaustion; anchoring to the old $48 high after that reversal is the classic chase trap.
• Binary print into a broken chart. With the Q2 report ~2026-08-04, the whole thesis reduces to one line — variable-royalty growth. Any deceleration below +25% YoY (versus +67% in Q1) re-rates the multiple down hard, and it lands while the chart offers no structural support beneath price.
• Insider selling into the run during the June melt-up, plus CFO Nicholas Hawkins retiring 2026-08-31 (announced 2026-05-08) with no named successor yet — a leadership-transition overhang.
• Valuation caught up. At the ~$36-37 area the stock trades near the ~$37.75 average sell-side target; the "undiscovered small-cap" edge that existed at ~$19.56 in early April is gone. Execution is now priced in.
• Small float (~44M shares, ~$1.5-1.6B cap) produces gappy tape that cuts both ways; the violence of the reversal is a feature of the structure.

Setup & Price Structure

The structure is in a post-blowoff repair phase. Reference levels from the June-July action: the $48.59 closing ATH (2026-06-30) is the anchor high; the ~$39 breakout shelf is now overhead resistance that has to be reclaimed to repair the trend; the early-July reaction low sits near $32-34. The late-week bounce to ~$36.61 (2026-07-10) into the mid-$30s read as short-covering and dip-testing rather than a confirmed higher-low base. Price since then needs re-validation against the current tape, but the map holds: under ~$39 the name is basing or broken, and a weekly close below $33 breaks the July reaction low and converts the reversal into a full trend break. A constructive re-entry needs a higher low above the low-$30s and a reclaim of $39 on expanding volume — better taken as a post-print continuation than a pre-print guess. RSI ran hot into the June top and the flush has worked off that excess, leaving the name neither an oversold bounce nor breakout-clean here.

Catalyst Calendar (next 30 days)

• 2026-08-31: CFO Nicholas Hawkins retirement (announced 2026-05-08). A successor announcement ahead of this date is a watch item — transition clarity or continued overhang.
• No FDA/regulatory or index-rebalance events pending inside the window.

Elapsed catalysts

• ~2026-08-04 (est.): Q2 2026 earnings — the binary. Watch variable royalties (+67% YoY in Q1; deceleration below +25% YoY is thesis-breaking), the FY26 guide ($91-95M) revision, and Q2 revenue against the $23-24M guide. Cadence is estimated off the 2026-05-12 Q1 print, so the date could slip to early-to-mid August. (passed 5d ago)
• 2026-07-14 (just passed): Arm partnership expansion for processor-core security assurance — incremental ecosystem-integration datapoint, not a standalone price catalyst. (passed 26d ago)

What Would Change Our Mind

• Turns constructive: a higher low that holds above the low-$30s followed by a weekly close back above $39 on expanding volume, ideally confirmed by a Q2 print keeping variable royalties above +40% YoY. That repairs the structure and re-opens a momentum-continuation entry.
• Confirms the break: a weekly close below $33 breaks the July reaction low; separately, a Q2 variable-royalty line below +25% YoY breaks the fundamental thesis independent of the chart.
• Stays noise: single -7% to -8% sessions on ~44M-share float are normal volatility for this name and do not by themselves change the read.

Correlation Notes

Arteris levers the same AI-semiconductor beta as the large-cap complex (NVDA, TSMC, Broadcom, Marvell) and the HBM/custom-silicon supply chain — it amplifies that exposure, it does not diversify it. Royalties are a downstream, lagged read on unit shipments across that ecosystem, so a broad AI-capex or custom-silicon-demand wobble reaches AIP with a delay and with more torque given the small float. Automotive/ADAS design wins (Li Auto, SiEngine) add a second-order tie to the China auto-silicon cycle. Any AIP exposure should be treated as concentrated AI-semi risk, correlated with existing large-cap chip names rather than additive to them.